Abstract Library

#4521 [18F]FDG (FDG) PET/CT metrics as prognostic biomarkers in the AGITG NABNEC trial

Introduction: NABNEC was a prospective phase II trial investigating carboplatin/nab-paclitaxel in patients with advanced Grade 3 NENs (NCT02215447).

Conference:

Presenting Author: Kong G

Authors: Kong G, Ayati N, Brown C, Siu D, Mak W,

Keywords: Prognostic marker, prospective trial, chemotherapy, PET imaging, FDG, metabolic tumour volume, suv,

#3569 Outcomes of Streptozotocin (STZ)-based chemotherapy (CT) in patients with advanced pancreatic neuroendocrine tumors (pNETs): Data from the Spanish Taskforce of Neuroendocrine and Endocrine Tumors (GETNE) national registry (R-GETNE)

Introduction: STZ-based CT has been used for advanced pNETs with rapid growth, high tumor load or progression to somatostatin analogues (SSA). Evidence supporting use of STZ-based CT in pNET is mainly retrospective, and there is an unmet need of prospective trials in this setting. We present data from the R-GETNE regarding the use of STZ in spanish centers.

Conference:

Presenting Author:

Authors: Esteban-Villarrubia J, Hernando J, Garcia A, Jimenez-Fonseca P, Teulé A,

Keywords: Streptozotocin, Chemotherapy, pNET, GETNE, R-GETNE,

#3516 177Lutetium-Peptide Receptor Radionuclide Therapy (PRRT) safety assessment in patients with refractory Gastro-Entero-Pancreatic Neuroendocrine Tumors (GEP NETs)

Introduction: 177Lu-PRRT became an established therapeutic modality in inoperable or metastatic NETs, demonstrating substantial survival benefits and reassuring safety profile. Dosimetry of Organs-At-Risk [OAR, kidneys, bone marrow (BM) and spleen] and malignant lesions ensures to further optimize its safety and efficacy.

Conference:

Presenting Author: van Bogaert C

Authors: van Bogaert C, Mileva M, Marin G, Levillain H, Artigas-Guix C,

Keywords: PRRT, Safety, Dosimetry, Prospective trial,

#3476 A phase II single arm trial evaluating the efficacy and safety of Temozolomide for second-line treatment of neuroendocrine carcinomas progressing after first-line platinum-based therapy

Introduction: Second-line treatment for neuroendocrine carcinoma (NEC) have been investigated in prospective trials, with only few prospective trials ongoing. Therefore, there is no consensus on the second-line regimen to use in patients with progressive NEC. These patients have generally a poor performance status (PS) and the tolerance to combination therapy is low. Metronomic temozolomide showed, in retrospective trials, a good safety and efficacy profile.

Conference:

Presenting Author:

Authors: Cannella L, von Arx C, Bracigliano A, Pizzolorusso A, Antonella D,

Keywords: neuroendocrine, temozolomide, NEC, Treatment,

#1929 Safety and Efficacy of High Doses Lanreotide Treatment in Patients with Progressive Neuroendocrine Tumors: Results from a Prospective Phase II Trial

Introduction: To date no systematic prospective trials have been carried out to evaluate safety and efficacy of unconventional doses of somatostatin analogs (SSAs) in neuroendocrine tumors (NETs). However,dose escalation of SSAs is a common strategy.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Albertelli M, Campana D, Faggiano A, Spada F, Baldelli R,

Keywords: SSA high dose,